Chlamydia pneumoniae is an obligatory intracellular bacterium that causes acute respiratory diseases, and is also believed to be involved in chronic inflammatory diseases, e.g. asthma. It can usually be treated with antibiotics but for some people the allergy towards certain antibiotics can prevent their use. In our previous study we used computational methods to find commercially available com-pounds that would inhibit the growth of Chlamydia pneumoniae. From the tens of thousands of compounds screened, 33 were purchased and tested in vitro. Several compounds showed promising activity without showing any toxicity towards the host cells. Five of the tested com-pounds (substituted benzimidazoles) were of special interest because although they were struc-turally very similar, they showed quite dissimilar biological activity. This implies that further variation of the structure could lead to even more potent compounds. The next step in the project is to synthesize new compounds based on the previously discov-ered active compounds. The new compounds will then be tested for their biological activity. The data from the biological testing are then used to design new compounds, which are synthesized and submitted for testing. This cycle of synthesis -> testing -> design -> synthesis is repeated to find compounds with optimal properties and enhanced activity towards Chlamydia pneumoniae.
Vastaava tutkija
Yli-Kauhaluoma Jari, Helsingin yliopisto, Farmasian tiedekunta, Farmaseuttisen kemian osasto Hankkeen kesto 2007 - 2007
Asiasanat
keuhkoklamydia, Chlamydia pneumoniae, lääkekemia, heterosykliset yhdisteet, bentsi-midatsolit, orgaaninen synteesi, asymmetrinen synteesi
Hankkeen vaihe: päättynyt
HUOM! Tämä tutkimushankekuvaus on tuotettu Hankehaaviin Helsingin yliopiston TUHTI-tutkimustietojärjestelmästä, jota ei enää ylläpidetä. Tarkista ajantaiset tutkimushanketiedot Helsingin yliopiston TUHAT-järjestelmästä.
|